Aktuellt
SENASTE
Redeye maintains its positive view of Orexo after the Q3 report. Although Zubzolv® revenue growth is primarily explained by favorable currency we are encouraged by the positive results from Orexo’s clinical phase I trial with the company’s nasal epinephrine (adrenaline), OX640. We reiterate our base case of SEK42 per share.
LÄS MER
